|[September 09, 2013]
Research and Markets: Obesity - Pipeline Review, H2 2013
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/kj3x85/obesity)
has announced the addition of the "Obesity
- Pipeline Review, H2 2013" report to their offering.
'Obesity - Pipeline Review, H2 2013', provides an overview of the
indication's therapeutic pipeline. This report provides information on
the therapeutic development for Obesity, complete with latest updates,
and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Obesity.
- A snapshot of the global therapeutic scenario for Obesity.
- A review of the Obesity products under development by companies and
universities/research institues based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
- Coverage of the Obesity pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Boehringer Ingelheim GmbH
Shionogi & Co., Ltd.
Eli Lilly and Company
Isis Pharmaceuticals, Inc.
Merck & Co., Inc.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Chong Kun Dang Pharmaceutical
Glenmark Pharmaceuticals Ltd.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi (News - Alert) Tanabe Pharma Corporation
and much more...
For more information visit http://www.researchandmarkets.com/research/kj3x85/obesity
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]